{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:42:21Z","timestamp":1789864941371,"version":"4.0.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T00:00:00Z","timestamp":1606176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013226","name":"Les Laboratories Pierre Fabre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007075","name":"European Society for Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023368","name":"Eisai Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023368","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.esmoop.2020.100019","type":"journal-article","created":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T10:30:40Z","timestamp":1609842640000},"page":"100019","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)"],"prefix":"10.1016","volume":"6","author":[{"given":"B.","family":"Pellegrino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Cavanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Boggiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Zamagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Frassoldati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Schirone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Caldara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Piacentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Berardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.A.","family":"Brandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Foglietta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Todeschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Tognetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Naldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Bortesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Montemurro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ardizzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Boni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Musolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.esmoop.2020.100019_bib1","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J\u00a0Clin Invest"},{"issue":"29","key":"10.1016\/j.esmoop.2020.100019_bib2","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1200\/JCO.2014.56.7479","article-title":"Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2 negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline","volume":"32","author":"Partridge","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2020.100019_bib3","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2020.100019_bib4","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s10549-008-0086-2","article-title":"Pattern of metastatic spread in triple-negative breast cancer","volume":"115","author":"Dent","year":"2009","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.esmoop.2020.100019_bib5","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10549-017-4529-5","article-title":"Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990\u20132010","volume":"167","author":"Malmgren","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.esmoop.2020.100019_bib6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejca.2018.03.015","article-title":"Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort","volume":"96","author":"Gobbini","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2020.100019_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-0-387-74039-3_1","article-title":"Overview of resistance to systemic therapy in patients with breast cancer","volume":"608","author":"Gonzalez-Angulo","year":"2007","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.esmoop.2020.100019_bib8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.breast.2019.07.006","article-title":"Metronomic chemotherapy for advanced breast cancer patients in the real world practice: final results of the VICTOR-6 study","volume":"48","author":"Cazzaniga","year":"2019","journal-title":"Breast"},{"issue":"6","key":"10.1016\/j.esmoop.2020.100019_bib9","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.2147\/TCRM.S3120","article-title":"Gemcitabine and taxanes in metastatic breast cancer: a systematic review","volume":"4","author":"Glueck","year":"2008","journal-title":"Ther Clin Risk Manag"},{"issue":"5","key":"10.1016\/j.esmoop.2020.100019_bib10","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1351\/pac198658050701","article-title":"Halichondrins \u2013 antitumor polyether macrolides from a marine sponge","volume":"58","author":"Hirata","year":"1986","journal-title":"Pure Appl Chem"},{"issue":"16","key":"10.1016\/j.esmoop.2020.100019_bib11","doi-asserted-by":"crossref","first-page":"4796","DOI":"10.1021\/ja00302a042","article-title":"Norhalichondrin A: an antitumor polyether macrolide from a marine sponge","volume":"107","author":"Uemura","year":"1985","journal-title":"J\u00a0Am Chem Soc"},{"issue":"33","key":"10.1016\/j.esmoop.2020.100019_bib12","doi-asserted-by":"crossref","first-page":"7927","DOI":"10.1021\/bi900776u","article-title":"Macromolecular interaction of halichondrin B analogues eribulin (E7389) and ER-076349 with tubulin by analytical ultracentrifugation","volume":"48","author":"Alday","year":"2009","journal-title":"Biochemistry"},{"issue":"18","key":"10.1016\/j.esmoop.2020.100019_bib13","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1200\/JCO.2008.17.7618","article-title":"Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"27","author":"Vahdat","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"25","key":"10.1016\/j.esmoop.2020.100019_bib14","doi-asserted-by":"crossref","first-page":"3922","DOI":"10.1200\/JCO.2009.25.8467","article-title":"Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine","volume":"28","author":"Cortes","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 15","key":"10.1016\/j.esmoop.2020.100019_bib15","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1200\/jco.2010.28.15_suppl.1081","article-title":"Efficacy and safety of eribulin in Japanese patients (pts) with advanced breast cancer","volume":"28","author":"Iwata","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"9769","key":"10.1016\/j.esmoop.2020.100019_bib16","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.esmoop.2020.100019_bib17","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/annonc\/mdw203","article-title":"Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy","volume":"27","author":"Pivot","year":"2016","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2020.100019_bib18","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1038\/bjc.2015.343","article-title":"A\u00a0phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium","volume":"113","author":"Lheureux","year":"2015","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2020.100019_bib19","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2020.100019_bib23","unstructured":"Technologies Corporation L. TaqMan\u00ae Universal PCR Master Mix User Guide (Pub. no. 4304449 Rev. E),\u00a02014."},{"issue":"1","key":"10.1016\/j.esmoop.2020.100019_bib24","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/tpj.2012.54","article-title":"Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependent cellular cytotoxicity in colorectal cancer treated with cetuximab therapy","volume":"14","author":"Negri","year":"2014","journal-title":"Pharmacogenomics J"},{"issue":"11","key":"10.1016\/j.esmoop.2020.100019_bib25","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1200\/JCO.2007.14.8957","article-title":"Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2\/neu-positive metastatic breast cancer","volume":"26","author":"Musolino","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"706","key":"10.1016\/j.esmoop.2020.100019_bib26","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1126\/science.28.706.49","article-title":"Mendelian proportions in a mixed population","volume":"28","author":"Hardy","year":"1908","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.esmoop.2020.100019_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"issue":"282","key":"10.1016\/j.esmoop.2020.100019_bib29","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.esmoop.2020.100019_bib30","series-title":"Statistical Models: Theory and Practice","author":"Freedman","year":"2009"},{"issue":"3","key":"10.1016\/j.esmoop.2020.100019_bib31","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration","volume":"50","author":"Mantel","year":"1966","journal-title":"Cancer Chemother Rep"},{"issue":"5","key":"10.1016\/j.esmoop.2020.100019_bib32","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/s41591-018-0009-7","article-title":"Carboplatin in BRCA1\/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial","volume":"24","author":"Tutt","year":"2018","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.esmoop.2020.100019_bib33","first-page":"40","article-title":"Carboplatin and gemcitabine combination in metastatic triple-negative anthracycline-and taxane-pretreated breast cancer patients: a phase II study","volume":"23","author":"Maisano","year":"2011","journal-title":"J\u00a0Chemother"},{"issue":"34","key":"10.1016\/j.esmoop.2020.100019_bib34","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1200\/JCO.2014.55.2984","article-title":"Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer","volume":"32","author":"O'Shaughnessy","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2020.100019_bib35","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s00280-010-1390-1","article-title":"The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype","volume":"67","author":"Aogi","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1016\/j.esmoop.2020.100019_bib36","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10549-010-0824-0","article-title":"Efficacy of ixabepilone in ER\/PR\/HER2-negative (triple-negative) breast cancer","volume":"121","author":"Perez","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.esmoop.2020.100019_bib37","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.breast.2010.02.003","article-title":"Cisplatin-gemcitabine therapy in metastatic breast cancer: improved outcome in triple negative breast cancer patients compared to non-triple negative patients","volume":"19","author":"Koshy","year":"2010","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.esmoop.2020.100019_bib38","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","article-title":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Schmid","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2020.100019_bib39","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.esmoop.2020.100019_bib40","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2020.100019_bib41","doi-asserted-by":"crossref","first-page":"e000504","DOI":"10.1136\/esmoopen-2019-000504","article-title":"How I treat metastatic triple-negative breast cancer","volume":"4","author":"Caparica","year":"2019","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2020.100019_bib42","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3389\/fphar.2020.00445","article-title":"Toxicity and pharmacogenomic biomarkers in breast cancer chemotherapy","volume":"11","author":"Al-Mahayri","year":"2020","journal-title":"Front Pharmacol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920328842?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920328842?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:26:27Z","timestamp":1761855987000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702920328842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S2059702920328842"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2020.100019","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2020.100019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100019"}}